In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes
Helen J Lachmann, Philip Lowe, Sandra Daniela Felix, Christiane Rordorf, Kieron Leslie, Sheril Madhoo, Helmut Wittkowski, Stephan Bek, Nicole Hartmann, Sophie Bosset, Philip N Hawkins, Thomas Jung, Helen J Lachmann, Philip Lowe, Sandra Daniela Felix, Christiane Rordorf, Kieron Leslie, Sheril Madhoo, Helmut Wittkowski, Stephan Bek, Nicole Hartmann, Sophie Bosset, Philip N Hawkins, Thomas Jung
Abstract
The investigation of interleukin 1beta (IL-1beta) in human inflammatory diseases is hampered by the fact that it is virtually undetectable in human plasma. We demonstrate that by administering the anti-human IL-1beta antibody canakinumab (ACZ885) to humans, the resulting formation of IL-1beta-antibody complexes allowed the detection of in vivo-produced IL-1beta. A two-compartment mathematical model was generated that predicted a constitutive production rate of 6 ng/d IL-1beta in healthy subjects. In contrast, patients with cryopyrin-associated periodic syndromes (CAPS), a rare monogenetic disease driven by uncontrolled caspase-1 activity and IL-1 production, produced a mean of 31 ng/d. Treatment with canakinumab not only induced long-lasting complete clinical response but also reduced the production rate of IL-1beta to normal levels within 8 wk of treatment, suggesting that IL-1beta production in these patients was mainly IL-1beta driven. The model further indicated that IL-1beta is the only cytokine driving disease severity and duration of response to canakinumab. A correction for natural IL-1 antagonists was not required to fit the data. Together, the study allowed new insights into the production and regulation of IL-1beta in man. It also indicated that CAPS is entirely mediated by IL-1beta and that canakinumab treatment restores physiological IL-1beta production.
Figures
References
- Dinarello C.A., Renfer L., Wolff S.M. 1977. Human leukocytic pyrogen: purification and development of a radioimmunoassay.Proc. Natl. Acad. Sci. USA. 74:4624–4627
- Dinarello C.A. 2002. The IL-1 family and inflammatory diseases.Clin. Exp. Rheumatol. 20:S1–S13
- Veltri S., Smith J.W. 1996. Interleukin 1 trials in cancer patients: a review of the toxicity, antitumor and hematopoietic effects.Stem Cells. 14:164–176
- Agostini L., Martinon F., Burns K., McDermott M.F., Hawkins P.N., Tschopp J. 2004. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder.Immunity. 20:319–325
- Dinarello C.A. 2004. Unraveling the NALP-3/IL-1beta inflammasome: a big lesson from a small mutation.Immunity. 20:243–244
- Hoffman H.M., Mueller J.L., Broide D.H., Wanderer A.A., Kolodner R.D. 2001. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome.Nat. Genet. 29:301–305
- Aksentijevich I., Nowak M., Mallah M., Chae J.J., Watford W.T., Hofmann S.R., Stein L., Russo R., Goldsmith D., Dent P., et al. 2002. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases.Arthritis Rheum. 46:3340–3348
- Aksentijevich I., Putnam D., Remmers E.F., Mueller J.L., Le J., Kolodner R.D., Moak Z., Chuang M., Austin F., Goldbach-Mansky R., et al. 2007. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model.Arthritis Rheum. 56:1273–1285
- Hull K.M., Shoham N., Chae J.J., Aksentijevich I., Kastner D.L. 2003. The expanding spectrum of systemic autoinflammatory disorders and their rheumatic manifestations.Curr. Opin. Rheumatol. 15:61–69
- Aganna E., Martinon F., Hawkins P.N., Ross J.B., Swan D.C., Booth D.R., Lachmann H.J., Bybee A., Gaudet R., Woo P., et al. 2002. Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis.Arthritis Rheum. 46:2445–2452
- Prieur A.M. 2001. A recently recognised chronic inflammatory disease of early onset characterised by the triad of rash, central nervous system involvement and arthropathy.Clin. Exp. Rheumatol. 19:103–106
- Ogura Y., Sutterwala F.S., Flavell R.A. 2006. The inflammasome: first line of the immune response to cell stress.Cell. 126:659–662
- Sutterwala F.S., Ogura Y., Szczepanik M., Lara-Tejero M., Lichtenberger G.S., Grant E.P., Bertin J., Coyle A.J., Galan J.E., Askenase P.W., Flavell R.A. 2006. Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1.Immunity. 24:317–327
- Keller M., Ruegg A., Werner S., Beer H.D. 2008. Active caspase-1 is a regulator of unconventional protein secretion.Cell. 132:818–831
- Hawkins P.N., Lachmann H.J., McDermott M.F. 2003. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome.N. Engl. J. Med. 348:2583–2584
- Goldbach-Mansky R., Dailey N.J., Canna S.W., Gelabert A., Jones J., Rubin B.I., Kim H.J., Brewer C., Zalewski C., Wiggs E., Hill S., Turner M.L., Karp B.I., Aksentijevich I., Pucino F., Penzak S.R., Haverkamp M.H., Stein L., Adams B.S., Moore T.L., Fuhlbrigge R.C., Shaham B., Jarvis J.N., O'neil K., Vehe R.K., Beitz L.O., Gardner G., Hannan W.P., Warren R.W., Horn W., Cole J.L., Paul S.M., Hawkins P.N., Pham T.H., Snyder C., Wesley R.A., Hoffmann S.C., Holland S.M., Butman J.A., Kastner D.L. 2006. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1{beta} inhibition.N. Engl. J. Med. 355:581–592
- Hoffman H.M., Throne M.L., Amar N.J., Sebai M., Kivitz A.J., Kavanaugh A., Weinstein S.P., Belomestnov P., Yancopoulos G.D., Stahl N., Mellis S.J. 2008. Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies.Arthritis Rheum. 58:2443–2452
- Foell D., Wittkowski H., Roth J. 2007. Mechanisms of disease: a ‘DAMP’ view of inflammatory arthritis.Nat. Clin. Pract. Rheumatol. 3:382–390
- Smith D.E., Hanna R., Della F., Moore H., Chen H., Farese A.M., MacVittie T.J., Virca G.D., Sims J.E. 2003. The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action.Immunity. 18:87–96
- Dinarello C.A., Ikejima T., Warner S.J., Orencole S.F., Lonnemann G., Cannon J.G., Libby P. 1987. Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro.J. Immunol. 139:1902–1910
- Gattorno M., Tassi S., Carta S., Delfino L., Ferlito F., Pelagatti M.A., D'Osualdo A., Buoncompagni A., Alpigiani M.G., Alessio M., et al. 2007. Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations.Arthritis Rheum. 56:3138–3148
- Rammes A., Roth J., Goebeler M., Klempt M., Hartmann M., Sorg C. 1997. Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway.J. Biol. Chem. 272:9496–9502
- Vogl T., Tenbrock K., Ludwig S., Leukert N., Ehrhardt C., van Zoelen M.A., Nacken W., Foell D., van der Poll T., Sorg C., Roth J. 2007. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock.Nat. Med. 13:1042–1049
- Lachmann H.J., Kone-Paut I., Kuemmerle-Deschner J.B., Leslie K.S., Hachulla E., Quartier P., Gitton X., Widmer A., Patel N., Hawkins P.N. 2009. A randomized trial of canakinumab, a fully human anti-IL-1β antibody, in cryopyrin associated period syndromes.N. Engl. J. Med. In press
- Alten R., Gram H., Joosten L.A., Berg W.B., Sieper J., Wassenberg S., Burmester G., van Riel P., Diaz-Lorente M., Bruin G.J., Woodworth T.G., Rordorf C., Batard Y., Wright A.M., Jung T. 2008. The human anti-IL-1beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis.Arthritis Res. Ther. 10:R67.
- Foell D., Roth J. 2005. S100 proteins in monitoring inflammation: the importance of a gold standard and a validated methodology.J. Immunol. 175:3459–3460
Source: PubMed